International Journal of Multidisciplinary Research in Biotechnology, Pharmacy, Dental and Medical Sciences (IJMRBPDMS)

Cognitive Radiology: Artificial Intelligence in Oncology Imaging and Personalized Cancer Care

Somashekhar SP[1]

[1]Department of Surgical Oncology, Aster InternationalInstitute of Oncology, Aster Hospital, Aster CMI Hospital,No. 43/2, New Airport Road, NH44, Sahakar Nagar, Hebbal,Bangalore 560092, India drspsomashekhar@gmail.com

ABSTRACT

Background:
Medical imaging plays a central role throughout the cancer care continuum, supporting early detection, diagnosis, staging, treatment planning, therapeutic monitoring, and long-term surveillance. However, the increasing complexity and volume of imaging data generated by computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), ultrasound, mammography, and hybrid imaging technologies have exceeded the interpretive capacity of conventional radiological workflows. Recent advances in artificial intelligence (AI), computational imaging, radiomics, radiogenomics, multimodal learning, and cognitive radiology have transformed oncology imaging by enabling automated image interpretation, quantitative biomarker extraction, molecular prediction, and personalized clinical decision support. Cognitive radiology refers to the integration of AI with advanced medical imaging to emulate aspects of expert radiological reasoning through continuous analysis of imaging, pathology, genomics, laboratory investigations, electronic health records, and longitudinal clinical information. Machine learning, deep learning, transformer architectures, foundation models, graph neural networks, reinforcement learning, and explainable artificial intelligence have significantly enhanced tumor detection, lesion characterization, treatment response assessment, adaptive imaging, and personalized cancer management. Despite remarkable progress, challenges remain regarding data standardization, interoperability, computational scalability, algorithmic transparency, regulatory validation, cybersecurity, and equitable clinical implementation. This review provides a comprehensive overview of cognitive radiology and artificial intelligence in oncology imaging, highlighting computational foundations, current clinical applications, emerging innovations, and future perspectives for personalized cancer care.[1]

Keywords: *Cognitive radiology, Artificial intelligence, Oncology imaging, Radiomics, Radiogenomics, Precision medicine, Medical imaging, Deep learning, Personalized cancer care, Clinical decision support.*

Article Info
Received: 05 April 2026, received in revised form: 15 April 2026, accepted: 20 April 2026, available online: 30 April 2026; Volume: 2; Issue: 4; Pages: 30-39.

Citation: Somashekhar SP., 2026. Cognitive Radiology: Artificial Intelligence in Oncology Imaging and Personalized Cancer Care. *International Journal of Multidisciplinary Research in Biotechnology, Pharmacy, Dental and Medical Sciences (IJMRBPDMS)* 2(4): 30-39.
DOI:

Introduction

Medical imaging represents one of the most essential components of modern oncology, providing critical information throughout cancer screening, diagnosis, staging, treatment planning, therapeutic monitoring, and long-term surveillance. Advances in computed tomography, magnetic resonance imaging, positron emission tomography, ultrasound, mammography, and hybrid imaging have dramatically improved visualization of tumor biology while supporting increasingly personalized approaches to cancer care. Nevertheless, the rapidly growing volume and complexity of imaging data present substantial challenges for radiologists, particularly in busy clinical environments.[2]

Traditional radiological interpretation relies primarily on visual assessment performed by experienced clinicians. Although this approach remains indispensable, subtle imaging biomarkers associated with tumor heterogeneity, molecular alterations, therapeutic response, and disease progression may remain difficult to recognize using conventional qualitative assessment alone. Furthermore, interobserver variability, increasing imaging workload, and growing demands for precision medicine have highlighted the need for intelligent computational support.[3]

Artificial intelligence has emerged as one of the most transformative technologies in diagnostic imaging by enabling automated analysis of complex medical images with remarkable accuracy. Deep learning algorithms identify tumors, segment anatomical structures, quantify disease burden, characterize imaging phenotypes, and predict molecular biomarkers directly from imaging studies. Simultaneously, multimodal artificial intelligence integrates imaging with pathology, genomics, laboratory investigations, and electronic health records into comprehensive computational models supporting individualized clinical decision-making.[4]

Cognitive radiology extends conventional image interpretation by combining artificial intelligence, radiomics, radiogenomics, natural language processing, and clinical reasoning into intelligent imaging ecosystems capable of continuously learning from multimodal biomedical information. Rather than replacing radiologists, cognitive radiology enhances physician expertise through evidence-based decision support, predictive analytics, and adaptive learning.[5]

The integration of artificial intelligence into oncology imaging has therefore become one of the foundational technologies supporting precision medicine by enabling personalized diagnosis, prognostic prediction, therapeutic optimization, and continuous disease monitoring throughout the cancer care continuum.[6]

2. Evolution of Cognitive Radiology

Radiology has undergone remarkable transformation since the introduction of X-ray imaging, progressing through computed tomography, magnetic resonance imaging, positron emission tomography, hybrid imaging, digital radiography, and advanced image-guided interventions. Each technological innovation substantially improved visualization of anatomical structures and disease processes while expanding the role of imaging in modern medicine.[7]

The transition from analog to digital imaging enabled acquisition, storage, and analysis of enormous quantities of radiological information through Picture Archiving and Communication Systems (PACS), electronic health records, and cloud-based healthcare infrastructure. These digital datasets subsequently became valuable resources for development of machine learning and artificial intelligence algorithms capable of automated image interpretation.[8]

Early artificial intelligence applications primarily focused on computer-aided detection and computer-aided diagnosis using handcrafted image features and conventional machine learning methods. Although these systems improved diagnostic consistency, they remained limited by manually engineered features and relatively modest predictive performance.[9]

The emergence of deep learning revolutionized cognitive radiology by enabling convolutional neural networks to automatically extract hierarchical imaging features directly from raw medical images. More recently, transformer architectures, multimodal foundation models, graph neural networks, and generative artificial intelligence have further expanded computational capabilities, supporting comprehensive integration of imaging, pathology, genomics, laboratory investigations, and clinical documentation.[10]

Today, cognitive radiology represents an intelligent computational ecosystem in which artificial intelligence continuously assists radiologists throughout image acquisition, reconstruction, interpretation, reporting, treatment planning, and longitudinal patient management.[11]

3. Computational Foundations of Artificial Intelligence in Radiology

Artificial intelligence-driven cognitive radiology relies upon multiple complementary computational methodologies capable of interpreting complex imaging information across anatomical, physiological, molecular, and clinical domains. Rather than functioning as isolated image classification algorithms, modern radiological systems integrate several artificial intelligence models operating simultaneously throughout the imaging workflow.[12]

Traditional machine learning algorithms including logistic regression, support vector machines, random forests, decision trees, and gradient boosting methods initially demonstrated considerable success in lesion classification, disease prediction, and outcome forecasting using structured imaging biomarkers. Although effective, these approaches generally depended upon manually engineered image features and limited biological representation.[13]

Deep learning substantially expanded computational capabilities by automatically extracting hierarchical representations from high-dimensional imaging data. Convolutional neural networks revolutionized tumor detection, anatomical segmentation, lesion classification, and image reconstruction, whereas recurrent neural networks facilitated temporal analysis of longitudinal imaging examinations.[14]

Transformer architectures have recently become central to cognitive radiology because self-attention mechanisms efficiently integrate imaging findings, pathology reports, laboratory biomarkers, genomic information, physician documentation, and electronic health records into unified patient-specific computational representations supporting individualized diagnosis and treatment planning.[15]

Foundation models pretrained on enormous multimodal biomedical datasets further enhance scalability through transfer learning, allowing adaptation across numerous cancer types while improving robustness, generalizability, and computational efficiency.[16]

4. Multimodal Imaging and Precision Oncology

Precision oncology depends fundamentally upon integration of radiological imaging with molecular biology, pathology, laboratory investigations, genomics, and longitudinal clinical information. Cancer is characterized by dynamic interactions among genetic mutations, immune responses, metabolism, angiogenesis, tumor microenvironment, and therapeutic exposure. Consequently, isolated imaging findings rarely capture the complete biological complexity of malignant disease.[17]

Computed tomography provides detailed anatomical information regarding tumor morphology, metastatic spread, lymph node involvement, and treatment response. Magnetic resonance imaging contributes superior soft-tissue characterization, functional imaging, diffusion-weighted imaging, and perfusion analysis. Positron emission tomography enables assessment of tumor metabolism, molecular activity, and functional response to therapy. Ultrasound and mammography further support disease detection, image-guided interventions, and longitudinal surveillance.[18]

Artificial intelligence harmonizes these heterogeneous imaging modalities with digital pathology, genomic sequencing, laboratory biomarkers, electronic health records, and clinical documentation through multimodal representation learning. These computational models identify hidden biological relationships beyond conventional radiological interpretation while supporting highly individualized precision oncology.[19]

Continuous integration of newly acquired imaging examinations throughout diagnosis, treatment, recurrence, and survivorship enables adaptive computational learning that substantially enhances personalized cancer management.[20]

5. Artificial Intelligence in Tumor Detection and Diagnosis

Accurate tumor detection represents one of the earliest and most successful applications of artificial intelligence in oncology imaging. Deep learning algorithms have demonstrated exceptional diagnostic performance across multiple imaging modalities by automatically identifying malignant lesions while reducing observer variability and improving diagnostic consistency.

Convolutional neural networks detect pulmonary nodules, breast lesions, brain tumors, liver metastases, prostate cancer, colorectal malignancies, pancreatic tumors, ovarian masses, and numerous other malignancies using computed tomography, magnetic resonance imaging, mammography, ultrasound, and positron emission tomography. Automated lesion detection substantially improves diagnostic sensitivity while reducing interpretation time in busy radiology practices.[21]

Artificial intelligence further assists radiologists by distinguishing benign from malignant lesions, estimating tumor aggressiveness, identifying multifocal disease, and supporting differential diagnosis through quantitative image analysis. These computational systems improve early diagnosis while facilitating timely therapeutic intervention.[22]

6. Radiomics: Quantitative Imaging Biomarkers

Radiomics has fundamentally transformed oncology imaging by extracting hundreds of quantitative imaging biomarkers from routine clinical examinations. Unlike conventional qualitative interpretation, radiomics objectively characterizes tumor morphology, texture, shape, vascularity, metabolism, heterogeneity, spatial organization, and temporal evolution using advanced computational analysis.

Artificial intelligence identifies subtle quantitative imaging signatures associated with tumor biology, molecular alterations, treatment response, recurrence risk, and patient survival. These imaging biomarkers substantially enhance prognostic prediction while supporting individualized therapeutic planning across diverse cancer types.[23]

Radiomics further enables longitudinal assessment of tumor evolution by quantifying changes in imaging biomarkers throughout chemotherapy, immunotherapy, targeted therapy, radiation therapy, and surgical intervention. Continuous integration of serial imaging examinations improves monitoring of therapeutic effectiveness and facilitates early identification of treatment resistance.[24]

7. Radiogenomics and Imaging-Based Molecular Prediction

Radiogenomics represents one of the most promising translational applications of cognitive radiology by linking radiological imaging with genomic and molecular information. This interdisciplinary field seeks to identify imaging phenotypes that reflect underlying molecular characteristics of tumors, enabling non-invasive prediction of clinically significant genetic alterations and therapeutic targets.[25]

Artificial intelligence algorithms analyze radiomic features together with genomic sequencing, transcriptomics, proteomics, and molecular biomarkers to establish complex associations between tumor morphology and molecular biology. These computational models enable prediction of driver mutations, gene expression profiles, molecular subtypes, immune characteristics, homologous recombination deficiency, microsatellite instability, and treatment sensitivity directly from routine imaging examinations.[26]

Radiogenomics further supports continuous molecular assessment throughout disease progression because serial imaging examinations can repeatedly evaluate tumor biology without requiring invasive tissue biopsies. Integration of imaging with molecular diagnostics therefore enables adaptive precision oncology while improving patient comfort and clinical efficiency.[27]

The combination of radiomics, radiogenomics, multimodal artificial intelligence, and cognitive radiology represents a major step toward truly personalized imaging-guided cancer care capable of continuously adapting to each patient's evolving disease biology.[28]

8. Artificial Intelligence in Treatment Response Assessment

Accurate evaluation of therapeutic response remains one of the most important responsibilities of oncologic imaging. Conventional response assessment methods, including RECIST criteria, primarily rely on changes in tumor size and may not fully capture the complex biological effects of modern therapies such as immunotherapy, targeted therapy, and precision medicine. Artificial intelligence significantly enhances treatment response evaluation by integrating quantitative imaging biomarkers, molecular characteristics, laboratory investigations, and longitudinal clinical information into comprehensive predictive models.[29]

Deep learning algorithms analyze serial computed tomography, magnetic resonance imaging, positron emission tomography, and hybrid imaging studies to identify subtle changes in tumor morphology, vascularity, metabolism, texture, and tissue composition that may precede measurable alterations in lesion size. Early identification of treatment response enables clinicians to optimize therapy while minimizing unnecessary toxicity and avoiding ineffective interventions.[30]

Artificial intelligence further distinguishes true disease progression from pseudoprogression, treatment-related inflammation, radiation-induced changes, and post-treatment fibrosis, thereby improving clinical decision-making and reducing diagnostic uncertainty throughout cancer management.[31]

9. Artificial Intelligence in Radiation Oncology Imaging

Radiological imaging plays a central role in radiation oncology by supporting tumor localization, target delineation, treatment planning, image-guided radiotherapy, adaptive radiation therapy, and post-treatment surveillance. Artificial intelligence has significantly improved each stage of this workflow through automated image analysis and quantitative assessment.

Deep learning algorithms automatically segment tumors, organs at risk, lymph node regions, and surrounding normal tissues with remarkable precision. Automated contouring substantially reduces treatment planning time while improving consistency among radiation oncologists.[32]

Artificial intelligence also supports adaptive radiation therapy by continuously integrating sequential imaging acquired during treatment. Computational models estimate anatomical changes, predict radiation sensitivity, evaluate treatment response, and recommend individualized modifications to dose distribution according to each patient's evolving anatomy and tumor biology.[33]

10. Artificial Intelligence in Image-Guided Surgery

Image-guided surgery increasingly depends on advanced radiological visualization to improve operative planning and intraoperative decision-making. Artificial intelligence enhances surgical precision through three-dimensional reconstruction, automated anatomical segmentation, tumor localization, vascular mapping, and prediction of resection margins.

Preoperative imaging integrated with deep learning enables surgeons to simulate multiple operative approaches before entering the operating room. During surgery, artificial intelligence further assists navigation systems by continuously analyzing intraoperative imaging, anatomical landmarks, and instrument positioning while improving surgical accuracy and minimizing injury to surrounding healthy tissues.[34]

Future integration of cognitive radiology with robotic surgery, augmented reality, mixed reality visualization, and real-time imaging is expected to further improve operative safety, surgical precision, and patient outcomes across numerous oncological procedures.[35]

11. Artificial Intelligence in Clinical Decision Support

Artificial intelligence has evolved beyond isolated image interpretation toward intelligent clinical decision-support systems capable of integrating imaging findings with pathology, genomics, laboratory investigations, medication history, and electronic health records. These systems provide radiologists and multidisciplinary oncology teams with comprehensive patient-specific recommendations supporting individualized clinical management.

Machine learning algorithms estimate tumor stage, recurrence probability, treatment response, progression-free survival, overall survival, and therapeutic toxicity by integrating heterogeneous biomedical information into unified computational frameworks. Interactive dashboards allow clinicians to visualize disease evolution, compare treatment strategies, and evaluate individualized risk estimates while maintaining physician oversight.[36]

Such intelligent decision-support systems improve communication among radiologists, oncologists, surgeons, pathologists, radiation oncologists, and molecular biologists while facilitating evidence-based multidisciplinary cancer care.[37]

12. Artificial Intelligence in Drug Discovery and Clinical Trials

Radiological imaging increasingly contributes to precision drug development by providing quantitative biomarkers capable of evaluating therapeutic efficacy throughout clinical trials. Artificial intelligence substantially accelerates this process through automated image analysis, treatment response prediction, patient stratification, and computational simulation.

Machine learning algorithms integrate radiomics, molecular imaging, pharmacology, genomics, and systems biology to identify novel therapeutic targets, predict treatment sensitivity, estimate toxicity, and optimize dosing strategies before laboratory or clinical testing. These computational approaches improve candidate selection while reducing research costs and development time.[38]

Artificial intelligence also improves clinical trial design by identifying patients most likely to benefit from investigational therapies, reducing trial variability, optimizing recruitment, and supporting adaptive trial methodologies. Imaging-derived biomarkers further facilitate development of objective surrogate endpoints for evaluating treatment effectiveness.[39]

13. Explainable Artificial Intelligence in Cognitive Radiology

Clinical implementation of artificial intelligence requires transparent computational models capable of explaining diagnostic and therapeutic recommendations. Explainable artificial intelligence (XAI) addresses this requirement by providing interpretable visual and quantitative explanations rather than functioning as opaque "black-box" systems.

Saliency maps and attention heatmaps identify image regions contributing most strongly to diagnostic predictions, enabling radiologists to verify that algorithms focus on biologically relevant anatomical structures. SHAP (Shapley Additive Explanations) values quantify the contribution of imaging biomarkers, laboratory investigations, genomic alterations, and clinical variables to individualized predictions, while counterfactual explanations demonstrate how modifications in patient characteristics influence predicted outcomes.[40]

Explainable artificial intelligence strengthens physician confidence, facilitates multidisciplinary communication, reduces algorithmic bias, supports regulatory approval, and promotes responsible implementation of cognitive radiology in routine oncology practice.[41]

14. Federated Learning, Cybersecurity, and Ethical Considerations

Large-scale development of artificial intelligence requires collaboration among hospitals, imaging centers, research institutions, and international oncology networks. However, direct sharing of sensitive imaging data raises important concerns regarding patient privacy, confidentiality, cybersecurity, and ethical governance.

Federated learning enables collaborative artificial intelligence development without transferring raw patient imaging data between institutions. Each participating center trains algorithms locally using its own imaging datasets, while only encrypted model parameters are securely aggregated into improved global models. This decentralized approach preserves patient confidentiality while enabling continuous learning from geographically diverse populations.[42]

Additional privacy-preserving technologies—including differential privacy, secure multi-party computation, homomorphic encryption, blockchain-based audit systems, and encrypted cloud computing—further strengthen cybersecurity within cognitive radiology ecosystems. Robust authentication mechanisms, encrypted communication protocols, intrusion detection systems, identity management, and continuous threat monitoring remain essential because artificial intelligence platforms continuously exchange highly sensitive radiological, molecular, and clinical information across interconnected healthcare infrastructures.[43]

15. Digital Biomarkers and Continuous Imaging Surveillance

The rapid expansion of digital health technologies has significantly enhanced longitudinal cancer imaging by enabling continuous integration of radiological examinations with physiological monitoring, laboratory biomarkers, wearable devices, and electronic health records. Unlike conventional follow-up strategies based solely on scheduled imaging, artificial intelligence enables continuous surveillance through integration of multimodal digital biomarkers reflecting disease progression, therapeutic response, and overall patient health.[44]

Artificial intelligence continuously analyzes serial computed tomography, magnetic resonance imaging, positron emission tomography, ultrasound, laboratory biomarkers, physiological measurements, and patient-reported outcomes to identify early evidence of recurrence, treatment resistance, metastatic progression, or therapy-related complications before overt clinical deterioration occurs. These predictive models support individualized surveillance schedules while minimizing unnecessary imaging and radiation exposure.

Continuous integration of digital biomarkers enables radiologists and oncologists to adapt follow-up strategies according to each patient's biological characteristics, treatment response, and individualized recurrence risk, thereby improving long-term cancer management and survivorship.[45]

16. Artificial Intelligence in Cancer Screening and Early Detection

Early cancer detection remains one of the most effective strategies for reducing cancer-related mortality. Artificial intelligence has substantially improved screening programs by increasing diagnostic accuracy, reducing false-positive findings, and identifying subtle imaging abnormalities that may remain undetected during conventional interpretation.

Deep learning algorithms have demonstrated remarkable performance in mammography, low-dose computed tomography for lung cancer screening, prostate magnetic resonance imaging, colorectal imaging, liver imaging, and cervical screening by automatically identifying suspicious lesions requiring further investigation. These computational systems improve screening efficiency while reducing interobserver variability and diagnostic workload.[46]

Artificial intelligence also enables individualized screening strategies through integration of imaging findings, family history, genomic susceptibility, environmental exposures, lifestyle factors, and clinical risk profiles. Personalized screening recommendations improve early detection while reducing unnecessary investigations among lower-risk populations.[47]

17. Emerging Innovations in Cognitive Radiology

Rapid advances in computational imaging continue to expand the capabilities of cognitive radiology. Foundation models trained on massive multimodal biomedical datasets are expected to improve diagnostic performance across diverse imaging modalities while requiring substantially less task-specific retraining.

Generative artificial intelligence has demonstrated considerable potential for image reconstruction, image enhancement, synthetic medical image generation, automated reporting, educational simulation, and hypothesis generation for biomedical research. Reinforcement learning algorithms further optimize imaging protocols by continuously learning from diagnostic outcomes and improving image acquisition strategies over time.[48]

Graph neural networks increasingly model complex biological relationships among imaging phenotypes, genomic alterations, molecular pathways, immune responses, and clinical outcomes, providing deeper understanding of cancer biology while supporting highly individualized precision oncology. These innovations are expected to further strengthen the role of artificial intelligence in next-generation oncology imaging.[49]

18. Integrated Intelligent Imaging Ecosystems

Future oncology imaging will increasingly operate within intelligent computational ecosystems integrating radiology, pathology, genomics, laboratory medicine, surgery, radiation oncology, medical oncology, pharmacy, and electronic health records into unified clinical platforms.

Artificial intelligence serves as the computational foundation connecting these diverse healthcare components through continuous multimodal learning and real-time clinical decision support. Such integrated ecosystems facilitate seamless communication among radiologists, oncologists, surgeons, pathologists, radiation oncologists, molecular biologists, and healthcare administrators while improving diagnostic accuracy, treatment coordination, medication safety, and patient-centered care.[50]

Cloud computing, edge computing, Internet of Medical Things (IoMT), blockchain technology, secure interoperability standards, and high-performance computational infrastructure will further improve scalability, accessibility, computational efficiency, and secure information exchange across future cognitive radiology networks.[51]

19. Future Perspectives

The future of cognitive radiology is increasingly centered on intelligent computational systems capable of continuously integrating imaging, pathology, genomics, molecular biology, laboratory investigations, wearable technologies, physiological monitoring, and longitudinal clinical information into adaptive patient-specific healthcare models.

Future research should prioritize large multicenter prospective studies evaluating the real-world clinical effectiveness of artificial intelligence across diverse imaging modalities, healthcare systems, and patient populations. Standardization of imaging acquisition, annotation protocols, validation methodologies, interoperability standards, explainability frameworks, and regulatory pathways will be essential for widespread clinical implementation.[52]

International collaboration among radiologists, oncologists, pathologists, biomedical engineers, computer scientists, regulatory agencies, healthcare organizations, and imaging researchers will accelerate development of trustworthy, scalable, and equitable artificial intelligence platforms capable of supporting routine oncology imaging worldwide.[53]

20. Discussion

Cognitive radiology represents one of the most significant advances in modern precision oncology by enabling comprehensive integration of multimodal imaging, radiomics, radiogenomics, pathology, genomics, laboratory investigations, and clinical information into intelligent computational frameworks.

Applications including tumor detection, molecular prediction, treatment response assessment, adaptive radiation therapy, image-guided surgery, drug development, cancer screening, and multidisciplinary clinical decision support demonstrate the broad clinical utility of artificial intelligence across the oncology imaging continuum. Rather than replacing radiologists, artificial intelligence functions as an intelligent clinical partner that enhances diagnostic confidence, workflow efficiency, and evidence-based decision-making while preserving physician expertise.[54]

Despite these remarkable advances, significant challenges remain. Data heterogeneity, interoperability limitations, algorithmic bias, computational complexity, cybersecurity concerns, ethical governance, regulatory approval, healthcare disparities, and clinician acceptance continue to represent substantial barriers. Addressing these challenges will require transparent governance, multidisciplinary collaboration, rigorous prospective validation, and internationally harmonized standards to ensure safe, equitable, and responsible implementation of cognitive radiology in clinical practice.[55]

21. Conclusion

Artificial intelligence is redefining oncology imaging through cognitive radiology by enabling comprehensive integration of multimodal biomedical information into individualized clinical decision-making. Through advanced analysis of computed tomography, magnetic resonance imaging, positron emission tomography, ultrasound, mammography, digital pathology, genomics, laboratory biomarkers, and electronic health records, artificial intelligence supports personalized diagnosis, molecular characterization, treatment optimization, recurrence monitoring, and long-term cancer surveillance.[56]

Continued advances in foundation models, explainable artificial intelligence, federated learning, multimodal learning, graph neural networks, reinforcement learning, and generative artificial intelligence are expected to further improve diagnostic accuracy, computational efficiency, scalability, interpretability, and accessibility across oncology imaging.[57]

Although important scientific, technical, ethical, and regulatory challenges remain, ongoing interdisciplinary research continues to accelerate translation of cognitive radiology into routine clinical practice. By supporting predictive analytics, quantitative imaging biomarkers, adaptive monitoring, and precision oncology, artificial intelligence has the potential to improve diagnostic performance, optimize therapeutic decision-making, enhance patient outcomes, and establish the foundation for the next generation of personalized cancer imaging worldwide.[58]

Future integration of cognitive radiology with digital biomarkers, multimodal precision medicine, advanced computational modeling, intelligent clinical decision support, and collaborative international imaging networks is expected to transform oncology imaging into a continuously learning healthcare ecosystem capable of delivering safer, more efficient, and truly individualized cancer care.[59]

As artificial intelligence technologies continue to mature and clinical validation expands across diverse healthcare settings, cognitive radiology is expected to become an indispensable component of precision oncology, enabling earlier diagnosis, more accurate prognostic assessment, optimized treatment planning, and improved survivorship outcomes for patients with cancer around the world.[60]

References

1. Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31–46. Doi:10.1158/2159-8290.CD-21-1059.
2. Singhal K, Azizi S, Tu T, et al. Large language models encode clinical knowledge. Nature. 2023;620(7972):172–180. Doi:10.1038/s41586-023-06291-2.
3. Kumar RMH. Childhood-Oncology Intelligence for Predicting Cancer Emergence, Optimizing Precision Therapies, and Simulating Lifelong Outcomes in Pediatric Malignancies Using Autonomous Foundation Models. Int J Drug Deliv Technol.2026;16(65s):162-173.DOI:10.25258/ijddt.16.65s.19
4. Moor M, Banerjee O, Abad ZSH, et al. Foundation models for generalist medical artificial intelligence. Nature. 2023;616(7956):259–265. Doi:10.1038/s41586-023-05881-4.
5. Rajendran LKK. Hematological Malignancy Identification via K-means based ROI Extraction. International Journal of Clinical Research in Medical Sciences. 2026;1(2):1-10. Doi:10.67231/kt1w3e73.

6. Maradi Hemanth Kumar R. Dynamic Digital Twins in Oncology: Foundation AI Models for Real-Time Predictive and Personalized Cancer Care. Power System Protection and Control. 2025;53(4):549-563. Doi:10.46121/pspc.53.4.38.
7. Kumar RMH. Pan-System Cancer Intelligence: Integrating Blood, Immune, Microbiome, and Tumor Microenvironment Data Using Foundation Models. Power System Protection and Control. 2023;51(4):92-100. Doi:10.46121/pspc.51.4.8.
8. Rajendran LKK. Identifying Determinants of Outcome in Post-Radiotherapy Cervical Carcinoma Requiring Adjuvant Surgery. International Journal of Clinical Research in Medical Sciences. 2026;1(2):1-10. Doi:10.67231/3acej759.
9. Maradi Hemanth Kumar R. AI-Driven Liquid Biopsy Systems for Early Cancer Detection and Personalized Oncology. Power System Protection and Control. 2023;51(4):66-83. Doi:10.46121/pspc.51.4.7.
10. Rajendran LKK. Machine Learning–Driven Symptom-Based Cancer Risk Stratification:A Systematic Review of Clinical Prediction Models and Methodological Rigor. Int J Drug Deliv Technol. 2026;16(40s):242-253.Doi:10.25258/ijddt.16.40s.26.
11. Kumar RMH. Maternal–Fetal Oncology Intelligence: Self-Evolving Foundation Models and Digital Twin Ecosystems for Precision Cancer Prediction, Treatment Optimization, and Maternal–Fetal Outcome Forecasting. Int J Drug Deliv Technol. 2026;16(65s):174-185. DOI: 10.25258/ijddt.16.65s.20
12. Rajendran OK. Bias, Fairness, and Ethical Challenges in Artificial Intelligence: A Comprehensive Review of Causes, Impacts, and Mitigation Strategies. Scientific Culture. 2026;12(2.1):13001-13010. Doi:10.5281/zenodo.20374091.
13. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nat Med. 2019;25(1):44–56. Doi:10.1038/s41591-018-0300-7.
14. Kumar RMH. Precision Oncofertility: Integrating Genomics, Reproductive Biomarkers, Treatment Toxicity Profiles, and Foundation Models for Fertility Preservation in Men and Women with Cancer. Int J Drug Deliv Technol. 2026;16(65s):186-200. DOI: 10.25258/ijddt.16.65s.21
15. Rajendran OK. Clinical Translation of Artificial Intelligence in Oncology: Real-World Validation, Workflow Integration, and Precision Medicine Applications. Int J Drug Deliv Technol. 2026;16(49s):956-964. Doi:10.25258/ijddt.16.49s.110.
16. Rajendran LKK. Interpretable Machine Learning for Early Mortality Prediction in Acute Myeloid Leukemia: A Decision Tree–Based Retrospective Cohort Study. Int J Drug Deliv Technol. 2026;16(40s):231-241.Doi:10.25258/ijddt.16.40s.25.
17. Kumar RMH. Self-Evolving Digital Twin Ecosystems for Early Detection and Precision Management of Breast, Lung, Colorectal, and Ovarian Cancers. Int J Drug Deliv Technol. 2026;16(65s):201-212. DOI: 10.25258/ijddt.16.65s.22
18. Esteva A, Robicquet A, Ramsundar B, et al. A guide to deep learning in healthcare. Nat Med. 2019;25(1):24–29. Doi:10.1038/s41591-018-0316-z.
19. Rajendran OK. Generative AI for Synthetic Medical Image Generation in Oncology: Addressing Data Scarcity in AI-Driven Cancer Diagnosis. Int J Drug Deliv Technol. 2026;16(49s):1010-1016. Doi:10.25258/ijddt.16.49s.117.
20. Rajendran LKK. Integrated Prognostic Modeling of Tumor Stage, Multimodal Therapy, and Functional Status in Lung Cancer Survival: A Real-World Cohort Study. Scientific Culture. 2026;12(5):567-576. Doi: 10.5281/zenodo.20738481.
21. Bommasani R, Hudson DA, Adeli E, et al. On the opportunities and risks of foundation models. arXiv. 2021. Doi:10.48550/arXiv.2108.07258.
22. Rajendran LKK. Integrative Pharmacogenomic Analysis of Drug Response Heterogeneity Across Cancer Cell Lines: Insights From Large-Scale GDSC Data. Scientific Culture. 2026;12(4):7537-7546. Doi:10.5281/zenodo.20767386.
23. Acs B, Rantalainen M, Hartman J. Artificial intelligence as the next step towards precision pathology. J Intern Med. 2020;288(1):62–81. Doi:10.1111/joim.13030.
24. Rajendran OK. Tumor Microenvironment Interaction-Guided Graph Neural Networks for Survival Prediction from Whole-Slide Pathology Images. Int J Drug Deliv Technol. 2026;16(49s):481-488. Doi:10.25258/ijddt.16.49s.50.
25. Rajendran LKK. Evaluating the Association of Cancer-Related Risk Factors With Multisystem Health: Insights Into Fertility, Cardiovascular, and Renal Indicators. Scientific Culture. 2026;12(4):7520-7527.Doi:10.5281/zenodo.20767374.
26. Rajendran LKK. From Prediction to Precision: An Externally Validated Deep Learning–Based Survival and Adjuvant Therapy Recommendation System for Resected Stage III Non–Small Cell Lung Cancer. Int J Drug Deliv Technol. 2026;16(30s):430-438.doi:10.25258/ijddt.16.30s.41.

27. Kumar RMH. Multimodal foundation AI models in precision oncology: Integrating radiomics, pathomics, multi-omics, and clinical intelligence systems. Power System Protection and Control. 2024;52(4):189-204. Doi:10.46121/pspc.52.4.16.
28. Rajendran LKK. From Prediction to Practice: A Machine Learning–Based Clinical Decision Support Tool for Bevacizumab Risk Stratification in Oncology. Int J Drug Deliv Technol. 2026;16(30s):414-429. Doi:10.25258/ijddt.16.30s.40.
29. Rajendran OK. Self-supervised multimodal Learning for early cancer detection across Imaging and genomics. Power System Protection and Control. 2024;52(4):167-178. Doi:10.46121/pspc.52.4.14.
30. Rajendran OK. Explainable AI-Driven Clinical. Decision Support Systems in Precision Oncology:Interpretable Models for Multimodal Cancer Care. Scientific Culture. 2026;12(2.1):12359-12369. Doi:10.5281/zenodo.20328194.
31. Rajendran LKK. Impact of Treatment Modalities on Fertility, Sexual Function, and Psychological Outcomes in Testicular Cancer Survivors: A Comprehensive Review. Int J Drug Deliv Technol. 2026;16(30s):447-453. Doi:10.25258/ijddt.16.30s.43.
32. Rajendran LKK. Intelligent Omics-Driven Patient Stratification for Cancer Therapeutic Re-profiling. International Journal of Clinical Research in Medical Sciences. 2026;1(1):1-11. Doi:10.67231/gvshck05.
33. Rajendran LKK. Cancer nanomedicine: utilizing the enhanced permeability and retention (EPR) effect to deliver high payloads of chemotherapeutic agents directly to tumor sites. Power System Protection and Control. 2024;52(2):123-129. Doi:10.46121/pspc.52.2.12.
34. Kather JN, Calderaro J. Development of AI in digital pathology. Nat Rev Clin Oncol. 2020;17(10):591–595. Doi:10.1038/s41571-020-00431-0.
35. Rajendran OK. AI-based radiogenomic Models for predicting immunotherapy response In solid tumors. Power System Protection and Control. 2023;51(4):24-37. Doi:10.46121/pspc.51.4.4.
36. Rajendran LKK. Enhanced Predictive Analytics for Early Malignancy Discovery in Routine Screening. International Journal of Clinical Research in Medical Sciences. 2026;1(1):1-10. Doi:10.67231/grams870.
37. Rajendran OK. Machine Learning-Based Prediction of Chemotherapy Toxicity in Colorectal Cancer: A Personalized Risk Stratification Approach. Scientific Culture. 2026;12(5.1):942-952. Doi:10.5281/zenodo.20767359.
38. Rajendran OK. Federated radiology AI Models for multi-institutional cancer diagnosis Without data sharing. Power System Protection And Control. 2023;51(4):38-54. Doi:10.46121/pspc.51.4.5.
39. Kumar RMH. AI-augmented immuno-oncology: Foundation models for predicting immune response, resistance, and precision immunotherapy. Power System Protection and Control. 2024;52(2):193-208. Doi:10.46121/pspc.52.2.18.
40. Rajendran OK. Deep Reinforcement Learning in Oncology: Advances in Cancer Imaging, Radiotherapy, and Personalized Treatment. Scientific Culture. 2026;12(5):597-606. Doi:10.5281/zenodo.20767337.
41. Rajendran OK. DEEP LEARNING FOR CROSS-MODALITY MAPPING BETWEEN HISTOPATHOLOGY AND RADIOLOGICAL IMAGING. Power System Protection and Control. 2025;53(3):313-328. Doi:10.46121/pspc.53.3.21.
42. Lu MY, Chen TY, Williamson DFK, et al. AI-based pathology predicts origins for cancers of unknown primary. Nature. 2021;594(7861):106–110. Doi:10.1038/s41586-021-03512-4.
43. Rajendran OK. Artificial Intelligence in Oncologic Imaging: Deep Learning, Radiomics, and Clinical Integration for Precision Cancer Diagnosis. Int J Drug Deliv Technol. 2026;16(50s):871-880. Doi:10.25258/ijddt.16.50s.92.
44. Bilal M, Raza SEA, Azam A, et al. Development and validation of a weakly supervised deep learning framework to predict the risk of colorectal cancer recurrence from histology images. Lancet Oncol. 2021;22(11):153–163. Doi:10.1016/S1470-2045(21)00430-5.
45. Rajendran OK. DIGITAL TWIN FRAMEWORKS FOR PERSONALIZED CANCER PROGRESSION MODELING USING LONGITUDINAL DATA. Power System Protection and Control. 2025;53(4):486-501. Doi:10.46121/pspc.53.4.33.
46. Rajendran LKK. Genomic profiling: utilizing Multi-omics data to identify potential Therapeutic targets and resistance markers. Power System Protection and Control. 2024;52(4):159-166. Doi:10.46121/pspc.52.4.13.
47. Rajendran OK. Artificial Intelligence–Driven Multimodal Imaging for Cancer During Pregnancy: Advances in Maternal–Fetal Diagnostics and Precision Oncology. Int J Drug Deliv Technol. 2026;16(50s):862-870. Doi:10.25258/ijddt.16.50s.91.
48. Rajendran LKK. Immunotherapy and cell Therapy: developing CAR-T cell therapies and Other immune-based treatments for cancer and Autoimmune diseases. Power System Protection and Control. 2023;51(2):64-77. Doi:10.46121/pspc.51.2.7.

49. Rajendran OK. FOUNDATION MODEL–DRIVEN PRECISION ONCOLOGY: INTEGRATING MULTI-OMICS, RADIOLOGY, AND CLINICAL DATA FOR PREDICTIVE CANCER CARE. Power System Protection and Control. 2024;52(2):154-163. Doi:10.46121/pspc.52.2.14.
50. Rajendran LKK. Theranostics: integrating Diagnostic imaging agents and therapeutic Drugs into a single multifunctional nano-Platform for real-time monitoring of treatment. Power System Protection and Control.2025;53(2):376-386. Doi:10.46121/pspc.53.2.31.
51. Rajendran LKK. Mechanisms driving Immunotherapy resistance in colorectal cancer Liver metastases. Power System Protection and Control. 2024;52(1):29-37. Doi:10.46121/pspc.52.1.5.
52. Ching T, Himmelstein DS, Beaulieu-Jones BK, et al. Opportunities and obstacles for deep learning in biology and medicine. J R Soc Interface. 2018;15(141):20170387. Doi:10.1098/rsif.2017.0387.
53. Litjens G, Kooi T, Bejnordi BE, et al. A survey on deep learning in medical image analysis. Med Image Anal. 2017;42:60–88. Doi:10.1016/j.media.2017.07.005.
54. Hemanth Kumar RM. Integrated Transcriptomic and 3 Learning Framework Identifies a Blood-Based Biomarker Signature for Anthracycline-Induced Cardiotoxicity in Juvenile Cancer Survivors. Int J Drug Deliv Technol. 2026;16(40s):219-230. Doi:10.25258/ijddt.16.40s.24.
55. Rajendran OK. DeepDRA: A Deep Learning Framework for Drug Repurposing and Cancer Drug Response Prediction Using Multi-Omics Data. Scientific Culture. 2026;12(3):68-77. Doi:10.5281/zenodo.20767428.
56. Mobadersany P, Yousefi S, Amgad M, et al. Predicting cancer outcomes from histology and genomics using convolutional networks. Proc Natl Acad Sci USA. 2018;115(13):E2970–E2979. Doi:10.1073/pnas.1717139115.
57. Lambin P, Leijenaar RTH, Deist TM, et al. Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol. 2017;14(12):749–762. Doi:10.1038/nrclinonc.2017.141.
58. Azizi S, Mustafa B, Ryan F, et al. Big self-supervised models advance medical image classification. Nature. 2021;594(7864):104–110. Doi:10.1038/s41586-021-03476-6.
59. Dosovitskiy A, Beyer L, Kolesnikov A, et al. An image is worth 16×16 words: transformers for image recognition at scale. arXiv. 2020. Doi:10.48550/arXiv.2010.11929.
60. Xu H, Usuyama N, Bagga J, et al. A whole-slide foundation model for digital pathology from real-world data. Nature. 2024;630(8015):181–188. Doi:10.1038/s41586-024-07441-w.